Maryland–based biotech NextCure acquired the rights to the CDH6-targeting antibody–drug conjugate (ADC) SIM0505 from Chinese company Simcere Zaiming for up to $745 million in combined upfront and ...

1State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, ...

Publishing in July 2025 to coincide with the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning, the series will continue through December 2025! Technological ...

First Disclosures in Molecular Cancer Therapeutics present drugs for the first time in published literature, accompanied by pertinent translational investigations. Submissions are assessed based on ...